Supported by
The main objective of the project is the development of a novel radiodiagnostic agent for imaging of breast cancer with γ-radiation computed tomography (SPECT) that will combine the ideal nuclear properties of technetium-99m (99mTc, γ-radiation), the most commonly used radionuclide in clinical practice, with those of the anticancer agent 2-(4΄-aminophenyl)benzothiazole that is known to be selectively taken up and metabolized by sensitive breast cancer cells. The presence of 2-(4΄-aminophenyl) benzothiazole is expected to selectively guide the 99mTc-agent to breast cancer tissue, thus allowing the imaging of the tumor through the emitted from 99mTc γ-radiation. The prospect for combined radiodiadiagnostic/radiotherapeutic applications through the use of alternative radioisotopes is tangible. In the market, there exists no specific imaging agent for the early and accurate diagnosis of breast cancer which is the most prevalent cancer in women and the commercial demand for such an agent is high.
